

Our Mission

The mission of Friends of FSH Research is to accelerate the discoveries that will lead to treatments or cures for FSH Muscular Dystrophy



Our Vision

That one day when FSH Muscular Dystrophy is diagnosed, the next words said are... "there is a treatment!"


2021-22 Annual Report June 1, 2021 - May 31, 2022

Fulcrum Therapeutics Clinical Trial Continues and SolveFSHD Joins the Fight!

In 2021-22, we continued to be impacted by the COVID-19 pandemic. We canceled our Gala planned for March, 2022 but continued to reach out to our supporters through our online Spring Forward Online Auction, hosted a Virtual Research Update Meeting, and participated in Giving Tuesday and GiveBIG. The Fulcrum Therapeutics clinical trial of a potential treatment for FSHD, which began in 2019, is continuing to collect data and assess the effectiveness of the treatment. Our funding strategy of taking a chance on unique, novel and riskier pilot projects helped two of our previous grant recipients, miRecule and Altay Therapeutics go on to obtain million dollar grants from SolveFSHD, a new Canadian company formed to help find a cure.

“Anthony Saleh of miRecule and I now hold a grant from the Maryland Industrial Partnerships Program to continue our work on a promising biomarker for FSHD, which Friends supported at its earliest stages. And I was recently informed that SolveFSHD will complement this funding for 2 years. I presented our work in Amsterdam recently and it was very well received. Thanks for all that Friends has done to support my studies.” - Robert Bloch, University of Maryland Oct 2022

Since 2005, our investment of **nearly \$6,500,000 in 80 research studies** (see chart below) is bringing us closer to a treatment or cure. We are getting closer to having a therapy for families living with the debilitating effects of FSHD – a disease that slowly destroys skeletal muscles in over half a million women and men around the world.




2021-22 Financial Summary

June 1, 2021 to May 31, 2022

In the fiscal year ending May 31, 2022, Friends of FSH Research:

- Invested \$409,718 in 14 research projects pursuing a treatment or cure for FSHD
- Continued to fund novel pilot projects with the potential to accelerate finding a treatment
- Provided funding to continue expansion of the FSHD Clinical Trial Research Network

Because of your support, we've been able to invest in research with the best chance of moving research forward at a faster pace and with a potential of attracting major funding support from other sources. The future is brighter today for people with FSHD, and you've played an important part in this achievement. Thank you to all our sponsors and donors for all you've done to help those living with FSHD.



Balance Sheet as of May 31, 2022

Year-End Assets	\$662,809
Year-End Liabilities	<u>170,347²</u>
Net Assets	\$492,462

²Funds committed to current research projects that are underway

Board of Directors

Terry Colella – President
Rick Colella – Treasurer
Premi Haynes
Erik Svenson

Brad Bagshaw – Vice President
Lynn Fischer
Elizabeth Jas
Karl Voss

George Shaw – Secretary
Chris Haven
Amanda Rickard

Scientific Advisory Board

Jeffrey S. Chamberlain, PhD – Director
Silvere M. van der Maarel, PhD
Gregory J. Block, MSc, PhD
Premi Haynes, PhD

Brian K. Kennedy, PhD
Dennis W. Shaw, MD
Bruce M. Wentworth, PhD

Amanda Rickard, BS
Rabi Tawil, MD
Kyoko Yokomori, PhD